Health insurance; creating the Ensuring Transparency in Prescription Drugs Prior Authorization Act; determination; consultation; prior authorization; effective date.
HB1808 creates the “Ensuring Transparency in Prescription Drugs Prior Authorization Act” and regulates how health insurers, pharmacy benefits managers (PBMs), and their utilization review entities handle prior authorization for prescription drugs. The bill requires plans to post prior authorization rules, clinical criteria, and formularies online in understandable language, and it requires advance notice before new or amended restrictions take effect. It also requires adverse determinations and appeals to be reviewed by appropriately licensed professionals, with appeals handled by someone not involved in the original denial and without a financial interest in the outcome.
The bill sets specific decision deadlines for prior authorization requests: 24 hours for urgent prescription drugs and four business days for nonurgent drugs once all necessary information is received. If a plan misses those deadlines after the provider submits the required information through the plan’s authorized system, the drug is deemed authorized. The bill also limits prior authorization for emergency health care services, extends approvals for chronic-condition drugs to three years in many cases, and requires plans to honor prior authorizations for at least 60 days when a patient changes health plans or products. Certain drugs, including opioids, some controlled substances, and weight-loss drugs, are excluded from the three-year chronic-condition rule.
HB1808 would amend Oklahoma insurance law by adding new sections to Title 36 and by creating enforcement authority for the Insurance Commissioner and the Attorney General. Violations can result in penalties of up to $5,000 per violation, subject to notice and hearing requirements. The bill also states that it applies to the Oklahoma Medicaid State Plan, while preserving any conflicting federal or Medicaid requirements. Its effective date is November 1, 2025.
The overall sentiment around the bill appears strongly favorable, as reflected by unanimous or near-unanimous committee votes and large bipartisan majorities on the floor in both chambers. The bill advanced through House and Senate committees without recorded opposition and passed final readings with only a small number of dissenting votes. That voting pattern suggests broad support for increasing transparency, limiting delays, and improving continuity of prescription drug coverage.
The main points of contention are likely to involve administrative burden, insurer and PBM discretion, and the cost or operational impact of faster approvals and longer authorization periods. The bill’s exceptions for opioids, controlled substances, and weight-loss drugs indicate some policy sensitivity around higher-risk or more heavily managed medications. Another potential issue is the bill’s interaction with federal law and the Medicaid State Plan, which the text repeatedly notes may limit application in some circumstances.
The bill adds a new regulatory framework in Title 36 governing prescription drug prior authorization by health carriers, PBMs, and utilization review entities. It requires disclosure of criteria and formularies, sets mandatory response times, limits retrospective denial and emergency-drug prior authorization, extends authorization validity for chronic conditions, and requires continuity of coverage when patients change plans. It also authorizes civil penalties enforced by the Insurance Commissioner and, for PBMs, the Attorney General, and expressly applies the act to the Oklahoma Medicaid State Plan to the extent permitted by law.
The bill appears to have enjoyed broad bipartisan support. It passed House and Senate committee votes unanimously or nearly unanimously, and it cleared floor votes by wide margins in both chambers. The voting history suggests lawmakers generally viewed the measure as a consumer-protection and transparency bill aimed at reducing delays in access to prescription drugs.
The likely areas of disagreement are the extent of regulation imposed on insurers and PBMs, the operational burden of shorter turnaround times and longer authorization periods, and whether automatic approval after missed deadlines could limit utilization management. The bill also raises implementation questions around Medicaid conformity, federal preemption, and the scope of exceptions for opioids, controlled substances, and weight-loss medications. Any opposition appears limited, given the strong vote totals, but concerns likely centered on cost, compliance, and medical-management flexibility.